Figure 4.

Therapeutic efficacy of DTSP and DTT-SP₄ vaccination in CT26 tumor model. (A) The time course of tumor injections and DTSP or DTT-SP₄ treatments. (B,C) Female BALB/c aged 6–8 weeks were challenged with CT26 cells (1 × 10⁵ cells/mouse) s.c. into the right flank. Two days after CT26 injection, the mice were pooled and assigned randomly (n = 5–8). DTSP, DTT-SP₄, FD^mut, or PBS formulated in Alum and CpG were administrated to the mice in the respective groups three times at 1-week interval. Tumors were monitored every 2–3 days and measured using a Vernier caliper. (B) Tumor growth curves were plotted by measuring tumor volume over time in each group. Data are presented as means ± SD. ^**p < 0.01, ^***p < 0.001, Student's t-test. (C) Kaplan–Meier survival curve. ^*p < 0.05, ^**p < 0.01, ^***p < 0.001, ns, not significant, log-rank (Mantel–Cox) test for significance.